MASKING CD94/NKG2A USING A NOVEL THERAPEUTIC MAB RESULTS IN SIGNIFICANT SUPPRESSION OF IL-6 LEVELS AND REDUCED OSTEOCLAST FORMATION IN RHEUMATOID ARTHRITIS EX VIVO CULTURES by Soderstrom, K, Sundstrom, Y, Berg, L, Schepis, D, Galsgaard, E, Klareskog, L, Wagtmann, N

Balance between activating NKG2D, DNAM-1, NKp44 and NKp46 and inhibitory CD94/NKG2A receptors determine natural killer degranulation towards rheumatoid arthritis synovial fibroblas... by Nielsen, N, Pascal, V, Fasth, A, Sundström, Y, Galsgaard, E, Ahern, D, Andersen, M, Baslund, B, Bartels, E, Bliddal, H, Feldmann, M, Malmström, V, Berg, L, Spee, P, Söderström, K

A genetics-led approach defines the drug target landscape of 30 immune-related traits by Fang, H, De Wolf, H, Knezevic, B, Burnham, K, Osgood, J, Sanniti, A, Lledó Lara, A, Kasela, S, De Cesco, S, Wegner, J, Handunnetthi, L, McCann, F, Chen, L, Sekine, T, Brennan, P, Marsden, B, Damerell, D, O’Callaghan, C, Bountra, C, Bowness, P, Sundström, Y, Milani, L, Berg, L, Göhlmann, H, Peeters, P, Fairfax, B, Sundström, M, Knight, J